Keytruda (pembrolizumab)

Numéro de dossier de l’APP: 21649
État des négociations:
Concluded with an LOI
Indication(s):
Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT
Promoteur/fabricant:
Merck Canada Inc.
Numéro de projet de l’ACMTS:
PC0236
Lettre-contrat de l’APP:
Conclusion du processus de négociation: